Blue Trust Inc. Sells 164 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Blue Trust Inc. decreased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 56.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127 shares of the biotechnology company’s stock after selling 164 shares during the quarter. Blue Trust Inc.’s holdings in Axon Enterprise were worth $75,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AXON. Geode Capital Management LLC raised its holdings in shares of Axon Enterprise by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after purchasing an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Axon Enterprise by 13.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after purchasing an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Axon Enterprise by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after purchasing an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in shares of Axon Enterprise in the 3rd quarter valued at about $200,000. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AXON shares. Robert W. Baird boosted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. TD Cowen started coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price target for the company. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Needham & Company LLC lifted their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, The Goldman Sachs Group lifted their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $561.31.

Axon Enterprise Stock Down 5.3 %

NASDAQ:AXON opened at $513.22 on Monday. The company has a market cap of $39.13 billion, a PE ratio of 132.62, a P/E/G ratio of 5.43 and a beta of 1.05. Axon Enterprise, Inc. has a twelve month low of $265.32 and a twelve month high of $715.99. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average is $619.94 and its two-hundred day moving average is $519.86.

Insiders Place Their Bets

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now directly owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Julie A. Cullivan sold 1,261 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the sale, the director now directly owns 2,392 shares in the company, valued at $1,631,487.52. This trade represents a 34.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,711 shares of company stock valued at $5,631,561. Insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.